Ekso Bionics Inc. (EKSO)
Ekso Bionics Statistics
Share Statistics
Ekso Bionics has 28.2M shares outstanding. The number of shares has increased by 37.16% in one year.
| Shares Outstanding | 28.2M |
| Shares Change (YoY) | 37.16% |
| Shares Change (QoQ) | 12.85% |
| Owned by Institutions (%) | 19.9% |
| Shares Floating | 26.3M |
| Failed to Deliver (FTD) Shares | 2.79K |
| FTD / Avg. Volume | 1.04% |
Short Selling Information
The latest short interest is 897.73K, so 3.18% of the outstanding shares have been sold short.
| Short Interest | 897.73K |
| Short % of Shares Out | 3.18% |
| Short % of Float | 3.41% |
| Short Ratio (days to cover) | 5.13 |
Valuation Ratios
The PE ratio is -1.09 and the forward PE ratio is -3.94. Ekso Bionics's PEG ratio is 0.02.
| PE Ratio | -1.09 |
| Forward PE | -3.94 |
| PS Ratio | 0.69 |
| Forward PS | 0.2 |
| PB Ratio | 0.97 |
| P/FCF Ratio | -1.25 |
| PEG Ratio | 0.02 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Ekso Bionics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.5, with a Debt / Equity ratio of 0.47.
| Current Ratio | 2.5 |
| Quick Ratio | 1.89 |
| Debt / Equity | 0.47 |
| Debt / EBITDA | -0.63 |
| Debt / FCF | -0.61 |
| Interest Coverage | -38.88 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $293.85K |
| Profits Per Employee | $-185.74K |
| Employee Count | 61 |
| Asset Turnover | 0.67 |
| Inventory Turnover | 1.84 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -70.68% in the last 52 weeks. The beta is 1.33, so Ekso Bionics's price volatility has been higher than the market average.
| Beta | 1.33 |
| 52-Week Price Change | -70.68% |
| 50-Day Moving Average | 0.47 |
| 200-Day Moving Average | 0.82 |
| Relative Strength Index (RSI) | 40.16 |
| Average Volume (20 Days) | 267.64K |
Income Statement
In the last 12 months, Ekso Bionics had revenue of 17.93M and earned -11.33M in profits. Earnings per share was -0.56.
| Revenue | 17.93M |
| Gross Profit | 9.51M |
| Operating Income | -10.46M |
| Net Income | -11.33M |
| EBITDA | -9.45M |
| EBIT | -11.06M |
| Earnings Per Share (EPS) | -0.56 |
Balance Sheet
The company has 6.49M in cash and 5.98M in debt, giving a net cash position of 510K.
| Cash & Cash Equivalents | 6.49M |
| Total Debt | 5.98M |
| Net Cash | 510K |
| Retained Earnings | -250.47M |
| Total Assets | 26.65M |
| Working Capital | 11.31M |
Cash Flow
In the last 12 months, operating cash flow was -9.85M and capital expenditures 0, giving a free cash flow of -9.85M.
| Operating Cash Flow | -9.85M |
| Capital Expenditures | 0 |
| Free Cash Flow | -9.85M |
| FCF Per Share | -0.49 |
Margins
Gross margin is 53.06%, with operating and profit margins of -58.35% and -63.21%.
| Gross Margin | 53.06% |
| Operating Margin | -58.35% |
| Pretax Margin | -63.21% |
| Profit Margin | -63.21% |
| EBITDA Margin | -52.74% |
| EBIT Margin | -58.35% |
| FCF Margin | -54.93% |
Dividends & Yields
EKSO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for EKSO is $5, which is 1182.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $5 |
| Price Target Difference | 1182.1% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
Stock Splits
The last stock split was on Mar 25, 2020. It was a backward split with a ratio of 1:15.
| Last Split Date | Mar 25, 2020 |
| Split Type | backward |
| Split Ratio | 1:15 |
Scores
| Altman Z-Score | -12.89 |
| Piotroski F-Score | 5 |